Komori
Kringle Pharma (4884) · PolicyRestated

Supporting patients and contributing to society through treatments for intractable diseases

First written in FY2020. 2 of 3 entries say "Restated". Latest entry: 2026-05-01.

3entries
7years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2020 – 2026-05-012020: 12021: 020212022: 120222023: 020232024: 020242025: 020252026: 12026
Same theme, other companies
Mission to support patients through treatments for intractable diseasesA theme 3 companies write about · 0 as a headwind · 3 as a tailwind

1 other company's latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. 2026-05-01RestatedOther Disclosures

    「The Company is a biotechnology venture company whose corporate philosophy is to contribute to society by researching and developing treatments for intractable diseases, providing breakthrough treatment options to patients suffering from intractable diseases, and promoting the in-house development of HGF protein drugs for rare diseases.」

    患者への治療手段の提供と社会貢献を企業理念として再掲している。
  2. FY2022RestatedAnnual report

    「Our corporate philosophy is to conduct research and development of treatments for intractable diseases, provide patients suffering from serious illnesses with innovative treatment options, and contribute to society」

    The company continues to uphold a corporate philosophy of providing patients with treatment options through the research and development of treatments for intractable diseases and contributing to society.
  3. FY2020First statedAnnual report

    「Conduct research and development of treatments for intractable diseases, provide patients suffering from serious illnesses with innovative treatment options, and contribute to society」

    The company’s corporate philosophy is to conduct research and development of treatments for intractable diseases and contribute to society by providing treatment options to patients.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Kringle Pharma yet. It last moved in the Other Disclosures of 2026-05-01: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Supporting patients and contributing to society through treatments for intractable diseases | Kringle Pharma,Inc. (4884) | Komori